BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29

• 

  Policy

  BioMarin Hit with DOJ Subpoena on Sponsored Testing for Rare Diseases

  The U.S. Department of Justice has slapped BioMarin Pharmaceutical with a subpoena in connection with its sponsored testing programs for the rare disease therapies Vivizim and Naglazyme.

  February 27, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Delivery

  GSK, Sanofi Exit Nigerian Market Amid Lingering Foreign Exchange Crisis

  The biopharma industry in Nigeria takes a hit as GSK and Sanofi shut down their commercialization efforts in the country.

  February 27, 2024

   · 

  4 min read

   · 

  Patience Asanga
• 

  Drug Development

  Minerva’s Schizophrenia Candidate Rejected by FDA in Complete Response Letter

  The FDA has rejected Minerva Neurosciences’ treatment for negative symptoms in schizophrenia, noting a lack of data and other factors that led to the Complete Response Letter.

  February 27, 2024

   · 

  2 min read

   · 

  Tyler Patchen
• 

  Business

  Novo Inks Potential $1.46B Deal to Tap Neomorph’s Molecular Glue Platform

  Under the collaboration and licensing agreement, Novo Nordisk and Neomorph are looking to discover, develop and commercialize novel molecular glue degraders for cardiometabolic and rare diseases.

  February 27, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Viking Scores Mid-Stage Win for Obesity Candidate, Eyes Lucrative Weight-Loss Market

  Viking Therapeutics announced Tuesday that its GLP-1/GIP receptor dual agonist helped patients lose up to nearly 15% of their weight over about three months in a Phase II study.

  February 27, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Delivery

  How Cell and Gene Therapy Manufacturing Will Evolve in 2024

  Cell and gene therapy professionals gathered in Miami last month to discuss new manufacturing approaches for these up-and-coming treatments.

  February 27, 2024

   · 

  5 min read

   · 

  Charlotte LoBuono
• 

  Business

  Baisong Mei’s Immigrant Journey Through American Biopharma

  From entering college in China at just 15 to co-inventing a drug for Bayer, Mei’s career journey has been far from average. Now CMO at Editas, he’s not done yet.

  February 27, 2024

   · 

  4 min read

   · 

  Mollie Barnes
• 

  Denali Secures $500M in Financing, Focuses on Large Molecule Biotherapeutics

  On the heels of layoffs, Denali Therapeutics has entered into a securities purchase agreement with existing accredited investors as it spins off preclinical small molecule portfolio.

  February 27, 2024

   · 

  2 min read

   · 

  Kate Goodwin
• 

  Policy

  Merck’s Bridion Could Face Generic Pressure from Hikma Ahead of Patent Expiry Date

  Despite a patent extension, Merck’s muscle relaxant reversal injection is now facing potential generic competition from Hikma Pharmaceuticals, which is seeking the FDA’s approval for a copycat version.

  February 27, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Career Advice

  Artificial Intelligence Is Set to Revolutionize Hiring Systems

  Companies are relying on artificial intelligence–powered applicant tracking systems to keep up the evolving recruitment demands. Here is how.

  February 27, 2024

   · 

  4 min read

   · 

  Sunitha Chari